| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/978-3-319-35072-1_12 |
| P698 | PubMed publication ID | 27553242 |
| P50 | author | Matteo Aldeghi | Q58796033 |
| Philip C. Biggin | Q60636399 | ||
| P2093 | author name string | Alexander Heifetz | |
| Michael J Bodkin | |||
| P2860 | cites work | Everything you wanted to know about Markov State Models but were afraid to ask | Q24616866 |
| Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 | Q24628577 | ||
| Predicting absolute ligand binding free energies to a simple model site | Q24683618 | ||
| Markov state models provide insights into dynamic modulation of protein function | Q26861597 | ||
| Exploiting protein intrinsic flexibility in drug design | Q38180428 | ||
| Drug-target residence time--a case for G protein-coupled receptors | Q38189272 | ||
| Systems biology brings new dimensions for structure-based drug design | Q38233920 | ||
| Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms | Q38286343 | ||
| Computational challenges of structure-based approaches applied to HIV. | Q38364829 | ||
| Design strategies to address kinetics of drug binding and residence time | Q38381796 | ||
| Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands | Q38398083 | ||
| AMPA receptor-positive allosteric modulators for the treatment of schizophrenia: an overview of recent patent applications | Q38421802 | ||
| Pentameric Ligand-gated Ion Channels : Insights from Computation | Q38452843 | ||
| Ligand Residence Time at G-protein-Coupled Receptors-Why We Should Take Our Time To Study It. | Q38543639 | ||
| The Dynamics of Drug Discovery. | Q38544120 | ||
| Direct calculation of the binding free energies of FKBP ligands | Q39131231 | ||
| Agonist and antagonist binding in human glycine receptors | Q39135614 | ||
| Hydration Site Thermodynamics Explain SARs for Triazolylpurines Analogues Binding to the A2A Receptor | Q39159119 | ||
| Compounds designed to fit a site of known structure in human haemoglobin | Q40016796 | ||
| A Strategy for the Chemotherapy of Infectious Disease | Q40081247 | ||
| On-the-Fly Learning and Sampling of Ligand Binding by High-Throughput Molecular Simulations. | Q40308189 | ||
| Functional insight into development of positive allosteric modulators of AMPA receptors. | Q41784821 | ||
| Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis | Q41807597 | ||
| MemProtMD: Automated Insertion of Membrane Protein Structures into Explicit Lipid Membranes. | Q42072255 | ||
| Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors | Q42164772 | ||
| Molecular simulations with solvent competition quantify water displaceability and provide accurate interaction maps of protein binding sites | Q42184980 | ||
| A conserved aromatic lock for the tryptophan rotameric switch in TM-VI of seven-transmembrane receptors | Q42241635 | ||
| Functional efficacy of adenosine A₂A receptor agonists is positively correlated to their receptor residence time | Q42246408 | ||
| NMDA receptor modulators: an updated patent review (2013-2014) | Q26997407 | ||
| Structure-based virtual screening for drug discovery: a problem-centric review | Q27022502 | ||
| Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core | Q27628494 | ||
| Predicting Ligand Binding Affinity with Alchemical Free Energy Methods in a Polar Model Binding Site | Q27657572 | ||
| Biostructural and pharmacological studies of bicyclic analogues of the 3-isoxazolol glutamate receptor agonist ibotenic acid | Q27665730 | ||
| Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators | Q27666167 | ||
| Structure based evolution of a novel series of positive modulators of the AMPA receptor | Q27666428 | ||
| Structural and Functional Analysis of Two New Positive Allosteric Modulators of GluA2 Desensitization and Deactivation | Q27667701 | ||
| Structure-kinetic relationship study of CDK8/CycC specific compounds | Q27677859 | ||
| Functional analysis of a novel positive allosteric modulator of AMPA receptors derived from a structure-based drug design strategy | Q27681406 | ||
| Pharmacological and structural characterization of conformationally restricted (S)-glutamate analogues at ionotropic glutamate receptors | Q27681743 | ||
| Chemoenzymatic synthesis of new 2,4-syn-functionalized (S)-glutamate analogues and structure-activity relationship studies at ionotropic glutamate receptors and excitatory amino acid transporters | Q27684003 | ||
| Molecular recognition of two 2,4-syn-functionalized (S)-glutamate analogues by the kainate receptor GluK3 ligand binding domain | Q27694588 | ||
| Binding mode of an α-amino acid-linked quinoxaline-2,3-dione analogue at glutamate receptor subtype GluK1 | Q27700165 | ||
| Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors | Q27731528 | ||
| Structure-based design of potent inhibitors of scytalone dehydratase: displacement of a water molecule from the active site | Q27766749 | ||
| Molecular dynamics simulations of GPCR-cholesterol interaction: An emerging paradigm | Q28080537 | ||
| Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors | Q28219491 | ||
| Extending the power of quantum chemistry to large systems with the fragment molecular orbital method | Q28303024 | ||
| Molecular mechanism for the dual alcohol modulation of Cys-loop receptors | Q28484223 | ||
| The role of flexibility and conformational selection in the binding promiscuity of PDZ domains | Q28484777 | ||
| Drug design for ever, from hype to hope | Q28732341 | ||
| Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis | Q29031166 | ||
| Modelling three-dimensional protein structures for applications in drug design. | Q30355473 | ||
| Locating missing water molecules in protein cavities by the three-dimensional reference interaction site model theory of molecular solvation. | Q30358933 | ||
| The Confine-and-Release Method: Obtaining Correct Binding Free Energies in the Presence of Protein Conformational Change | Q30372513 | ||
| The influence of cholesterol on membrane protein structure, function, and dynamics studied by molecular dynamics simulations. | Q30373374 | ||
| Protein crystallography for aspiring crystallographers or how to avoid pitfalls and traps in macromolecular structure determination | Q30409760 | ||
| Perspective: Alchemical free energy calculations for drug discovery | Q30422862 | ||
| Alchemical free energy methods for drug discovery: progress and challenges | Q30427576 | ||
| Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia | Q30428422 | ||
| Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. | Q30501558 | ||
| Pathway and mechanism of drug binding to G-protein-coupled receptors. | Q30503489 | ||
| Funnel metadynamics as accurate binding free-energy method | Q30539051 | ||
| SIGNAL TRANSDUCTION. Structural basis for nucleotide exchange in heterotrimeric G proteins | Q42390741 | ||
| Mechanism of voltage gating in potassium channels | Q42644041 | ||
| One Size Does Not Fit All: The Limits of Structure-Based Models in Drug Discovery | Q42659257 | ||
| AceCloud: Molecular Dynamics Simulations in the Cloud | Q42695719 | ||
| Quantifying water-mediated protein-ligand interactions in a glutamate receptor: a DFT study | Q42739559 | ||
| A comparative analysis of the role of water in the binding pockets of ionotropic glutamate receptors. | Q42881770 | ||
| Computational drug design accommodating receptor flexibility: the relaxed complex scheme | Q43992973 | ||
| Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study. | Q44760042 | ||
| The translocation kinetics of antibiotics through porin OmpC: insights from structure-based solvation mapping using WaterMap | Q45855155 | ||
| Contributions of water transfer energy to protein-ligand association and dissociation barriers: Watermap analysis of a series of p38α MAP kinase inhibitors | Q46377411 | ||
| Extracting hydration sites around proteins from explicit water simulations | Q46636331 | ||
| Thermodynamics of buried water clusters at a protein-ligand binding interface | Q46938920 | ||
| Comparison of several molecular docking programs: pose prediction and virtual screening accuracy. | Q47708648 | ||
| Rigorous Free Energy Calculations in Structure-Based Drug Design. | Q51613137 | ||
| Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders. | Q53447679 | ||
| Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs | Q56975993 | ||
| Copernicus | Q57082059 | ||
| Structure–Affinity Relationships (SARs) and Structure–Kinetics Relationships (SKRs) of Kv11.1 Blockers | Q63916704 | ||
| Analysis of ligand-bound water molecules in high-resolution crystal structures of protein-ligand complexes. | Q64977617 | ||
| Thermodynamic contributions of the ordered water molecule in HIV-1 protease | Q73442110 | ||
| Partial agonist activity of 11-cis-retinal in rhodopsin mutants | Q73674599 | ||
| 4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors | Q74247151 | ||
| The effect of water displacement on binding thermodynamics: concanavalin A | Q79934379 | ||
| Understanding kinase selectivity through energetic analysis of binding site waters | Q83030277 | ||
| Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase | Q83158635 | ||
| Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design | Q84351224 | ||
| Molecular dynamics simulations of membrane proteins | Q85831701 | ||
| Docking challenge: protein sampling and molecular docking performance | Q30607323 | ||
| Involvement of water in carbohydrate-protein binding. | Q30666622 | ||
| Data sharing matters | Q30735723 | ||
| The use of thermodynamic and kinetic data in drug discovery: decisive insight or increasing the puzzlement? | Q30881748 | ||
| Virtual screening of chemical libraries | Q33209939 | ||
| A high-throughput de novo sequencing approach for shotgun proteomics using high-resolution tandem mass spectrometry. | Q33537380 | ||
| Mapping of allosteric druggable sites in activation-associated conformers of the M2 muscarinic receptor | Q33577530 | ||
| Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases | Q33631185 | ||
| Not just an oil slick: how the energetics of protein-membrane interactions impacts the function and organization of transmembrane proteins. | Q33736493 | ||
| Do crystal structures obviate the need for theoretical models of GPCRs for structure-based virtual screening? | Q34049826 | ||
| Molecular dynamics simulations and drug discovery | Q34061019 | ||
| Hierarchical coarse-graining strategy for protein-membrane systems to access mesoscopic scales | Q34127406 | ||
| Molecular signatures of G-protein-coupled receptors | Q34327700 | ||
| Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator. | Q34360057 | ||
| GPCRDB: an information system for G protein-coupled receptors | Q34389708 | ||
| Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field | Q34459931 | ||
| Discovery of a novel binding trench in HIV integrase. | Q34546744 | ||
| Fighting obesity with a sugar-based library: discovery of novel MCH-1R antagonists by a new computational-VAST approach for exploration of GPCR binding sites | Q34670175 | ||
| Reduced lateral mobility of lipids and proteins in crowded membranes | Q34671799 | ||
| Role of Desolvation in Thermodynamics and Kinetics of Ligand Binding to a Kinase | Q34680443 | ||
| Role of the active-site solvent in the thermodynamics of factor Xa ligand binding | Q34748976 | ||
| Microsecond simulations indicate that ethanol binds between subunits and could stabilize an open-state model of a glycine receptor | Q34772214 | ||
| On the nature of partial agonism in the nicotinic receptor superfamily | Q34797005 | ||
| Conformational changes in talin on binding to anionic phospholipid membranes facilitate signaling by integrin transmembrane helices | Q35034161 | ||
| Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials | Q35051978 | ||
| AMPA receptor potentiators: from drug design to cognitive enhancement | Q35054673 | ||
| Kinetics of protein-ligand unbinding: Predicting pathways, rates, and rate-limiting steps | Q35062738 | ||
| Predictive power of molecular dynamics receptor structures in virtual screening | Q35073109 | ||
| Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery | Q35136572 | ||
| Homology Model Versus X-ray Structure in Receptor-based Drug Design: A Retrospective Analysis with the Dopamine D3 Receptor | Q35181896 | ||
| Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase | Q35243844 | ||
| Structure-based virtual screening for drug discovery: principles, applications and recent advances. | Q35282223 | ||
| Rational Design of a Novel AMPA Receptor Modulator through a Hybridization Approach | Q35379102 | ||
| Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor. | Q35616147 | ||
| Structural biology. Structural basis for chemokine recognition and activation of a viral G protein-coupled receptor | Q35652476 | ||
| Receptor-based virtual screening protocol for drug discovery. | Q35653355 | ||
| From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. | Q35671393 | ||
| Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents | Q35673318 | ||
| GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1-2 September 2014. | Q35830953 | ||
| Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. | Q36153010 | ||
| Molecular mechanism of 7TM receptor activation--a global toggle switch model | Q36364704 | ||
| Accurate calculation of the absolute free energy of binding for drug molecules | Q36427764 | ||
| Explaining why Gleevec is a specific and potent inhibitor of Abl kinase | Q36582978 | ||
| Calculation of protein-ligand binding affinities. | Q36698596 | ||
| An improved relaxed complex scheme for receptor flexibility in computer-aided drug design | Q36838120 | ||
| Are predicted protein structures of any value for binding site prediction and virtual ligand screening? | Q36859642 | ||
| A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents | Q37069448 | ||
| Subtype selective kainic acid receptor agonists: discovery and approaches to rational design | Q37214843 | ||
| Efficient drug lead discovery and optimization | Q37307959 | ||
| Binding of small-molecule ligands to proteins: "what you see" is not always "what you get". | Q37372747 | ||
| Energetics of displacing water molecules from protein binding sites: consequences for ligand optimization | Q37439036 | ||
| The therapeutic promise of positive allosteric modulation of nicotinic receptors | Q37695734 | ||
| Prediction of protein-ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations | Q37761334 | ||
| Limiting assumptions in structure-based design: binding entropy | Q37972732 | ||
| New insights from structural biology into the druggability of G protein-coupled receptors. | Q37998740 | ||
| A crystal clear solution for determining G-protein-coupled receptor structures | Q38025530 | ||
| Comparing proteins by their internal dynamics: exploring structure-function relationships beyond static structural alignments | Q38064010 | ||
| AMPA receptor positive allosteric modulators: a patent review | Q38081162 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | membrane protein | Q423042 |
| drug discovery | Q1418791 | ||
| P304 | page(s) | 161-181 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Advances in Experimental Medicine and Biology | Q4686385 |
| P1476 | title | Beyond Membrane Protein Structure: Drug Discovery, Dynamics and Difficulties | |
| P478 | volume | 922 |
| Q47348631 | Computational Methods Used in Hit-to-Lead and Lead Optimization Stages of Structure-Based Drug Discovery | cites work | P2860 |
Search more.